Drug Interaction-Informed Approaches to Inflammatory Bowel Disease Management

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2024 Nov 27

PMID 39598554

Authors

Kyeong-Ryoon Lee

Aneela Gulnaz

Yoon-Jee Chae

Affiliations

Soon will be listed here.

Abstract

Inflammatory bowel disease (IBD) is a complex and chronic condition that requires the use of various pharmacological agents for its management. Despite advancements in IBD research, the multifaceted mechanisms involved continue to pose significant challenges for strategic prevention. Therefore, it is crucial to prioritize safe and effective treatment strategies using the currently available pharmacological agents. Given that patients with IBD often require multiple medications due to combination therapy or other underlying conditions, a comprehensive understanding of drug interactions is essential for optimizing treatment regimens. In this review, we examined the pharmacological treatment options recommended in the current IBD management guidelines and provided a comprehensive analysis of the known pharmacokinetic interactions associated with these medications. In particular, this review includes recent research results for the impact of anti-drug antibodies (ADAs) on the concentrations of biological agents used in IBD treatment. By leveraging detailed interaction data and employing personalized dosing strategies, healthcare providers can improve therapeutic outcomes and minimize adverse effects, ultimately improving the quality of care for patients with IBD.

References

Zaher H, Khan A, Palandra J, Brayman T, Yu L, Ware J . Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse. Mol Pharm. 2006; 3(1):55-61. DOI: 10.1021/mp050113v. View

Oselin K, Anier K . Inhibition of human thiopurine S-methyltransferase by various nonsteroidal anti-inflammatory drugs in vitro: a mechanism for possible drug interactions. Drug Metab Dispos. 2007; 35(9):1452-4. DOI: 10.1124/dmd.107.016287. View

Imani S, Jusko W, Steiner R . Diltiazem retards the metabolism of oral prednisone with effects on T-cell markers. Pediatr Transplant. 1999; 3(2):126-30. DOI: 10.1034/j.1399-3046.1999.00027.x. View

Chen N, Cui D, Wang Q, Wen Z, Finkelman R, Welty D . In vitro drug-drug interactions of budesonide: inhibition and induction of transporters and cytochrome P450 enzymes. Xenobiotica. 2017; 48(6):637-646. DOI: 10.1080/00498254.2017.1344911. View

Sparrow M, Hande S, Friedman S, Lim W, Reddy S, Cao D . Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther. 2005; 22(5):441-6. DOI: 10.1111/j.1365-2036.2005.02583.x. View

Jostins L, Ripke S, Weersma R, Duerr R, McGovern D, Hui K . Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012; 491(7422):119-24. PMC: 3491803. DOI: 10.1038/nature11582. View

Zhuang Y, Xu Z, Frederick B, de Vries D, Ford J, Keen M . Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study. Clin Ther. 2011; 34(1):77-90. DOI: 10.1016/j.clinthera.2011.11.015. View

Zhang L, Wei M, Zhao C, Qi H . Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes. Acta Pharmacol Sin. 2008; 29(12):1507-14. DOI: 10.1111/j.1745-7254.2008.00908.x. View

Chen Y, Ma F, Jones N, Deng R, Li C, Li C . Assessment of CYP3A-mediated drug interaction via cytokine (IL-6) elevation for mosunetuzumab using physiologically-based pharmacokinetic modeling. CPT Pharmacometrics Syst Pharmacol. 2023; 13(2):234-246. PMC: 10864933. DOI: 10.1002/psp4.13073. View

10.

Manikandan P, Nagini S . Cytochrome P450 Structure, Function and Clinical Significance: A Review. Curr Drug Targets. 2017; 19(1):38-54. DOI: 10.2174/1389450118666170125144557. View

11.

Hande S, Wilson-Rich N, Bousvaros A, Zholudev A, Maurer R, Banks P . 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. Inflamm Bowel Dis. 2006; 12(4):251-7. DOI: 10.1097/01.MIB.0000206544.05661.9f. View

12.

Kuriakose A, Chirmule N, Nair P . Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications. J Immunol Res. 2016; 2016:1298473. PMC: 4942633. DOI: 10.1155/2016/1298473. View

13.

Kurzawski M, Dziewanowski K, Ciechanowski K, Drozdzik M . Severe azathioprine-induced myelotoxicity in a kidney transplant patient with thiopurine S-methyltransferase-deficient genotype (TPMT*3A/*3C). Transpl Int. 2005; 18(5):623-5. DOI: 10.1111/j.1432-2277.2005.00095.x. View

14.

Zemanova N, Lnenickova K, Vavreckova M, Anzenbacherova E, Anzenbacher P, Zapletalova I . Gut microbiome affects the metabolism of metronidazole in mice through regulation of hepatic cytochromes P450 expression. PLoS One. 2021; 16(11):e0259643. PMC: 8577747. DOI: 10.1371/journal.pone.0259643. View

15.

Feuerstein J, Isaacs K, Schneider Y, Siddique S, Falck-Ytter Y, Singh S . AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology. 2020; 158(5):1450-1461. PMC: 7175923. DOI: 10.1053/j.gastro.2020.01.006. View

16.

Colombel J, Sandborn W, Reinisch W, Mantzaris G, Kornbluth A, Rachmilewitz D . Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362(15):1383-95. DOI: 10.1056/NEJMoa0904492. View

17.

Adedokun O, Xu Z, Gasink C, Jacobstein D, Szapary P, Johanns J . Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease. Gastroenterology. 2018; 154(6):1660-1671. DOI: 10.1053/j.gastro.2018.01.043. View

18.

Zimm S, Collins J, ONeill D, Chabner B, Poplack D . Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. Clin Pharmacol Ther. 1983; 34(6):810-7. DOI: 10.1038/clpt.1983.254. View

19.

Wang B, Shen J, Zhou Q, Meng D, He Y, Chen F . Effects of naringenin on the pharmacokinetics of tofacitinib in rats. Pharm Biol. 2020; 58(1):225-230. PMC: 7144329. DOI: 10.1080/13880209.2020.1738504. View

20.

Lowry P, Franklin C, Weaver A, Szumlanski C, Mays D, Loftus E . Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut. 2001; 49(5):656-64. PMC: 1728490. DOI: 10.1136/gut.49.5.656. View